References
- Laskowski LK, Elbakoush F, Calvo J, et al. Evolution of the NBOMes: 25C- and 25B- Sold as 25I-NBOMe. J Med Toxicol. 2014;11:237–241
- Lawn W, Barratt M, Williams M, et al. The NBOMe hallucinogenic drug series: patterns of use, characteristics of users and self-reported effects in a large international sample. J Psychopharmacol (Oxford, England). 2014;28:780–788.
- Nikolaou P, Papoutsis I, Stefanidou M, et al. 2C-I-NBOMe, an “N-bomb” that kills with “Smiles”. Toxicological and legislative aspects. Drug Chem Toxicol. 2015;38:113–119.
- Ninnemann A, Stuart GL. The NBOMe series: a novel, dangerous group of hallucinogenic drugs. J Stud Alcohol Drugs. 2013;74:977–978.
- Srisuma S, Bronstein AC, Hoyte CO. NBOMe and 2C substitute phenylethylamine exposures reported to the National Poison Data System. Clin Toxicol (Phila). 2015;11:1–5.
- Tang MH, Ching CK, Tsui MS, et al. Two cases of severe intoxication associated with analytically confirmed use of the novel psychoactive substances 25B-NBOMe and 25C-NBOMe. Clin Toxicol (Philadelphia, PA.). 2014;52:561–565.
- Sporkert F, Augsburger M, Vilarino R, et al. (2013) Identification and implication of the phenethylamine derivative 25B-NBOMe in a case of an unresolved fatality. Paper presented at: The 51st Annual Meeting of the International Association of Forensic Toxicologists, Madeira, Portugal.
- Yoshida K, Saka K, Shintani-Ishida K, et al. A case of fatal intoxication due to the new designer drug 25B-NBOMe 2015. Forensic Toxicol. 2015;33:396–401.
- Poklis JL, Nanco CR, Troendle MM, et al. Determination of 4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine (25B-NBOMe) in serum and urine by high performance liquid chromatography with tandem mass spectrometry in a case of severe intoxication. Drug Test Anal. 2014;6:764–769.
- Zuba D, Sekuła K. Analytical characterization of three hallucinogenic N-(2-methoxy)benzyl derivatives of the 2C-series of phenethylamine drugs. Drug Test Anal. 2013;5:634–645.
- Zuba D, Sekuła K, Buczek A. 25C-NBOMe–new potent hallucinogenic substance identified on the drug market. Forensic Sci Int. 2013;227:7–14.
- EMCDDA. Risk Assessment Report of a new psychoactive substance: 2-(4-iodo-2,4-dimethoxyphenyl)-N-(2-methoxybenzy) ethanamine (25I-NBOMe). [Cited 2015 Aug 1] Available from: http://www.emcdda.europa.eu/attachements.cfm/att_228239_EN_25I-NBOMe
- Papoutsis I, Nikolaou P, Stefanidou M, et al. 25B-NBOMe and its precursor 2C-B: modern trends and hidden dangers. Forensic Toxicol. 2015;33:1–11
- Elz S, Kläs T, Warnke U, et al. Development of highly potent partial agonists and chiral antagonists as tools for the study of 5-HT2A-receptor mediated function. Naunyn-Schmiedeberg's Arch Pharmacol. 2002;365:R29
- Heim R. (2004). Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur [PhD thesis]. Free University Berlin. [Cited 2015 Aug 1] Available from: http://www.diss.fu-berlin.de/diss/receive/FUDISS_thesis_000000001221
- Ettrup A, Holm S, Hansen M, et al. Preclinical safety assessment of the 5-HT2A receptor agonist PET adioligand [11C]Cimbi-36. Mol Imaging Biol. 2013;15:376–383.
- Ettrup A, da Cunha-Bang S, McMahon B, et al. Serotonin 2A receptor agonist binding in the human brain with [11C]Cimbi-36. J Cereb Blood Flow Metab. 2014;34:1188–1196.
- Finnema SJ, Stepanov V, Ettrup A, et al. Characterization of [(11)C]Cimbi-36 as an agonist PET radioligand for the 5-HT(2A) and 5-HT(2C) receptors in the nonhuman primate brain. Neuroimage. 2014;84:342–353.
- Nichols DE, Frescas SP, Chemel BR, et al. High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective agonist radioligand. Bioorg Med Chem. 2008;16:6116–6123.
- Kelly A, Eisenga B, Riley B, et al. Case series of 25I-NBOMe exposures with laboratory confirmation. Clin Toxicol (Phila). 2012;50:702.
- Rose SR, Poklis JL, Poklis A. A case of 25I-NBOMe (25-I) intoxication: a new potent 5-HT2A agonist designer drug. Clin Toxicol (Phila). 2013;51:174.
- Hill SL, Doris T, Gurung S, et al. Severe clinical toxicity associated with analytically confirmed recreational use of 25I-NBOMe: case series. Clin Toxicol (Phila). 2013;51:487.
- Forrester MB. NBOMe designer drug exposures reported to Texas poison centers. J Addict Dis. 2014;33:196–201.
- Suzuki J, Dekker MA, Valenti ES, et al. Toxicities associated with NBOMe ingestion-a novel class of potent hallucinogens: a review of the literature. Psychosomatics. 2014;56:129–139.
- Wood DM, Sedefov R, Cunningham A, et al. Prevalence of use and acute toxicity associated with the use of NBOMe drugs. Clin Toxicol (Philadelphia, PA). 2015;53:85–92.
- Stellpflug SJ, Kealey SE, Hegarty CB, Janis GC. “2-(4-Iodo-2, 5-dimethoxyphenyl)-N-[(2-methoxyphenyl) methyl] ethanamine (25I-NBOMe): clinical case with unique confirmatory testing.” J Med Toxicol. 2014;10:45–50.
- Suzuki J, Poklis JL, Poklis A. “My friend said it was good LSD”: a suicide attempt following analytically confirmed 25I-NBOMe ingestion. J Psychoactive Drugs. 2014;46:379–382.
- Caldicott DG, Bright SJ, Barratt MJ. NBOMe – a very different kettle of fish. Med J Aust. 2013;199:322–323.
- Drug Enforcement Administration Office of Diversion Control Drug & Chemical Evaluation Section. 25I-NBOMe, 25C-NBOMe, and 25B-NBOMe (Street names: N-bomb, Smiles, 25I, 25C, 25B) November 2013 [Cited 2015 August 1] Available from: http://www.deadiversion.usdoj.gov/drug_chem_info/nbome.pdf
- Advisory Council on the Misuse of Drugs (ACMD). ‘‘NBOMe’’ compounds: a review of the evidence of use and harm; 2013 [Cited 2015 August 1] Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/204808/J_TCDO_report_on_5-6APB_and_NBOMe_compounds.pdf
- Walterscheid JP, Phillips GT, Lopez AE, et al. Pathological findings in 2 cases of fatal 25I-NBOMe toxicity. Am J Forensic Med Pathol. 2014;35:20–25.
- Andreasen MF, Telving R, Rosendal I, et al. A fatal poisoning involving 25C-NBOMe. Forensic Sci Int. 2015;251:e1–e8.
- Kueppers VB, Cooke CT. 25I-NBOMe related death in Australia: a case report. Forensic Sci Int. 2015;249:e15–18.
- Poklis JL, Devers KG, Arbefeville EF, et al. Postmortem detection of 25I-NBOMe [2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine] in fluids and tissues determined by high performance liquid chromatography with tandem mass spectrometry from a traumatic death. Forensic Sci Int. 2014;234:e14–e20.
- Rice, S. New hallucinogenic drug 25B-NBOMe and 25I-NBOMe led to South Australian man's bizarre death SA. The Advertiser September 12; 2012 [Cited 2015 Aug 1] Available from: http://www.news.com.au/national/south-australia/new-hallucinogenic-drug-25b-nbome-and-25i-nbome-led-to-south-australian-mans-bizarre-death/story-fndo4dzn-1226472672220
- Hasnie A. New synthetic drug investigated in Fishers teen’s death. Fox News; April 1 2014, [Cited 2015 Aug 1] Available from: http://fox59.com/2014/04/01/synthetic-drugs-may-have-killed-fishers-teen/
- Ralston N, Davies L. Teen jumps to his death after $1.50 drug hit. The Sydney Morning Herald; June 6, 2013 [Cited 2015 Aug 1] Available from: http://www.smh.com.au/nsw/teen-jumps-to-his-death-after-150-drug-hit-20130606-2nrpe.html